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Abstract Reticulocyte-type 15-lipoxygenase is known to dioxy-
genate phospholipids without preceding action of phospholipases
A2 (PLA2). Therefore we studied the reaction of the secretory
PLA2s (sPLA2) from pancreas and snake venom, and of the
human cytosolic PLA2 (cPLA2) with 1-palmitoyl-2-arachidonoyl
phosphatidylcholine (PAPC) and their 15-lipoxygenated species
(PAPC-OOH and PAPC-OH) either alone or as equimolar
mixtures. These PLA2s cleaved PAPC-O(O)H with higher
(sPLA2) or similar rates (cPLA2) as compared with native
PAPC. In mixtures, however, PAPC proved to be the preferred,
albeit not exclusive substrate for all three PLA2s. Thus, partial
15-lipoxygenation of phospholipids may also trigger liberation of
arachidonic acid.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Phospholipases A2 (PLA2s) constitute a family of signal
transduction enzymes, which catalyse fatty acid hydrolysis
from the sn-2 position of phospholipid with concomitant pro-
duction of lysophospholipid, a key event in the production of
in£ammatory lipid mediators, e.g. prostanoids, leukotrienes
and platelet-activating factor. Several PLA2 isoforms are cur-
rently considered as potential targets for this role [1^3]. While
the calcium-independent PLA2 (iPLA2) does not seem to mo-
bilise fatty acids, both cytosolic PLA2 (cPLA2) and secretory
PLA2s (sPLA2s) contribute to the total fatty acid turnover on
the basis of spatial and temporal characteristics of activation
and substrate preferences [4]. The liberated fatty acid is then
transformed by a number of eicosanoid-synthesising enzymes
to lipoxygenase products and prostanoids. Thus, arachidonic
acid (AA) can be converted by 15-lipoxygenases to (15S)-hy-
dro(pero)xy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid (15-
H(p)ETE) for which a number of biological actions have
been described [5]. Among the enzymes of the polyenoic fatty
acid metabolism, the 15-lipoxygenase of the reticulocyte type
including that occurring in human neutrophils as well as soy-
bean lipoxygenase-1 exhibit the peculiarity to react not only
with non-esteri¢ed polyenoic fatty acids but also with phos-
pholipids in the absence of preceding action of PLA2 [6^12].
By this way, phospholipids bearing a (15S)-hydroperoxy-
(5Z,8Z,11Z,13E)-eicosatetraenoyl residue or another hydro-
peroxy-polyenoic fatty acid residue at the sn-2 position are
formed, which may be subsequently reduced by phospholipid
hydroperoxide glutathione peroxidase to the corresponding
hydroxy derivatives [13,14]. Since the latter products have
been detected in rabbit reticulocytes [15,16], which contain
high levels of 15-lipoxygenase, 15-lipoxygenated phospholip-
ids should be considered as potential biological substrates
for PLA2s. A number of studies have been reported in which
a stimulation of the PLA2-mediated phospholipid breakdown
upon non-enzymatic lipid peroxidation or in the presence of
lipoxygenated phospholipid was observed [8,17^24]. From
these reports it could be assumed that a basic function of
PLA2s may be that of repairing enzymes against peroxidative
damage to membrane phospholipids in the cell. However,
many of these studies were inconsistent owing to the use of
chemically unde¢ned substrates (e.g. when the phospholipids
were subjected to non-enzymatic lipid peroxidation) or by
insu⁄cient analytical data to characterise quantitatively and
kinetically the PLA2 action. Moreover, most of the work was
done with snake venom PLA2 whereas mammalian PLA2s
were used in only a few cases [8,22,23]. In the present study,
we investigated the reactions of representatives of two main
subfamilies of PLA2, the 14 kDa sPLA2 (group I) and the 85
kDa cPLA2 (group IV) [2], on 1-palmitoyl-sn-2-arachidonoyl-
phosphatidylcholine (PAPC) and its 15-lipoxygenated deriva-
tives and provide comparative quantitative data on the liber-
ation of arachidonic acid and of its 15-lipoxygenase products.
2. Materials and methods
2.1. Preparation of 1-palmitoyl-2-[(15S)-hydroperoxy-(5Z,8Z,11Z,
13E)-eicosatetraenoyl]-phosphatidylcholine (PAPC-OOH)
and 1-palmitoyl-2-[(15S)-hydroxy-(5Z,8Z,11Z,13E)-
eicosatetraenoyl]-phosphatidylcholine (PAPC-OH)
PAPC-OOH was prepared by the use of soybean lipoxygenase ac-
cording to the procedure of Brash and co-workers [25] with some
modi¢cations. Brie£y, 780 Wg of 1-palmitoyl-2-arachidonoyl phospha-
tidylcholine (PAPC) were deprived of solvent and dissolved in 6 ml 10
mM sodium deoxycholate and 13 ml 0.2 M sodium borate bu¡er, pH
9.0, under sonication for 5 min. The reaction was started by addition
of 250 Wg of soybean lipoxygenase (Sigma, Germany) per 5.0 ml
sample at room temperature. After 10 min the reaction was stopped
by addition of 10 ml methanol and 5 ml chloroform. Thereafter 5 ml
water were added to produce phase separation. The combined organic
phases were evaporated and dissolved in the HPLC solvent methanol/
acetonitrile/water 90:6:4 (v/v/v) containing 20 mM choline chloride
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and subjected to reverse-phase HPLC on a Nucleosil 1005 C8 column
(Macherey and Nagel, Germany) on a LC-6A instrument (Shimadzu,
Japan) equipped with a diode-array detector SPD 1040A (Hewlett-
Packard, USA). The fractions were monitored at 210 nm for non-
converted substrate, 235 nm for lipoxygenated product and 270 nm
for conjugated trienes. Crude PAPC-OOH was eluted at a retention
time of about 7 min (£ow rate 0.8 ml/min) and was puri¢ed by
straight-phase HPLC (Zorbax Sil column 4.6 mmU150 mm; DuPont)
twice with the solvent n-hexane/2-propanol/water 4:6:1 (v/v/v). Pure
PAPC-OOH was eluted at 12.5 min (£ow rate 0.8 ml/min) and stored
at 380‡C under argon until used.
PAPC-OH was prepared similarly as PAPC-OOH except that the
enzymatic reaction product was reduced with 151 mM sodium boro-
hydride prior to extraction. The product was eluted at about 4 min
(£ow rate 0.8 ml/min) and at 14.2 min (£ow rate 0.6 ml/min) in
reverse-phase and straight-phase HPLC separations, respectively.
The yields were approximately 45% for PAPC-OOH and 64% for
PAPC-OH, respectively.
2.2. Phospholipase A2 assay
sPLA2 from Crotalus adamanteus venom (400 IU/mg protein) and
bovine pancreas sPLA2 (45 IU/mg protein) were purchased from Sig-
ma, Germany. The enzymes were dissolved in 10 mM sterile Tris-HCl
bu¡er, pH 8.0 to a concentration of 100 IU/ml. Puri¢ed human re-
combinant cPLA2 was a kind gift of Dr. Tibes (Boehringer Mann-
heim) and used in a concentration of 184 Wg protein/ml.
For the experiments with pure substrates, 25 WM of either PAPC,
PAPC-OOH or PAPC-OH was sonicated twice for 1 min in 1.0 ml
assay medium containing 10 mM Tris-HCl, pH 8.0, 150 mM NaCl
and 5 mM CaCl2 under argon atmosphere. The sPLA2 from C. ada-
manteus venom exhibited a very little activity at pH 8.0 and was
therefore measured at pH 9.0. The concentration of the phospholipids
was determined by fatty acid analysis upon alkaline hydrolysis. After
preincubation for 5 min the reaction was started with either 1 Wl
cPLA2, or 0.55 IU sPLA2 from bovine pancreas at 37‡C or 0.25 IU
sPLA2 from C. adamanteus venom at 25‡C. At various intervals 100
Wl aliquots were taken, mixed with 200 Wl methanol-acetic acid 98:2
containing 75 WM triphenylphosphine, and analysed for the liberation
of fatty acids by reverse-phase HPLC on a Nucleosil 100-7C18 column
(Macherey and Nagel, Germany) with a precolumn 5-C18-AB using
the mobile phase methanol/water/acetic acid 85:15:0.1 (v/v). The
peaks eluted at about 5 min (free 15-HETE) and 11.8 min (AA),
respectively with a £ow rate of 1.0 ml/min were quantitated by peak
area using calibration curves with authentic standards. For some ex-
periments, substrate mixtures consisting of 12.5 WM PAPC and 12.5
WM of either PAPC-OOH or PAPC-OH were used and treated as
above.
3. Results
3.1. Experiments with secretory phospholipases A2
In Figs. 1 and 2 are shown representative examples of a
series of experiments with sPLA2 from bovine pancreas.
This enzyme cleaved the pure 15-lipoxygenated phospholipids
with about 3^4-fold higher initial rates as compared with the
same concentration (25 WM) of PAPC within the ¢rst 5 min of
reaction period (Fig. 1). Following this period there occurred
a sharp decline of the cleavage of lipoxygenated phospholip-
ids, so that after 30 min two thirds or three quarters of them
were found to be uncleaved, respectively. This deviation from
linearity, which was much less pronounced with PAPC (Fig.
1), was apparently in part due to a product inhibition by free
15-HETE or 15-HpETE, respectively, as a partial inhibition
by 9 WM 15-HETE (the ¢nal concentration obtained under the
experimental conditions in Fig. 1) of the sn-2 cleavage of
PAPC was observed (data not shown). Comparatively much
higher reaction rates of sPLA2s (from porcine pancreas and
bee venom) with de¢ned oxygenated linoleyl phospholipids
versus the parent one were also observed by van den Berg
et al. who applied an indirect lipid monolayer technique for
measuring PLA2 activity, but did not analyse the fatty acids
liberated [22].
A quite opposite behaviour was observed when equimolar
mixtures of lipoxygenated and non-lipoxygenated phospholip-
ids were used as substrate. Under these conditions PAPC
turned out to be the strongly preferred substrate as compared
with its 15-lipoxygenated derivatives with respect to both ini-
tial rates and ¢nal values for various reaction periods (Fig. 2).
The initial rates of the liberation of arachidonic acid were
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Fig. 1. sn-2 cleavage of pure non-lipoxygenated (PAPC) and 15-lip-
oxygenated (PAPC-OOH and PAPC-OH) substrate by the sPLA2
from bovine pancreas. Conditions as described in Section 2. The
values of AA liberation (8) represent the mean þ S.D. of four sepa-
rate experiments. The values of 15-HpETE (E) and 15-HETE (O)
represent the mean of two experiments under identical conditions as
for AA.
Fig. 2. sn-2 cleavage of equimolar mixtures of non-lipoxygenated
(PAPC) and 15-lipoxygenated (PAPC-OOH and PAPC-OH) sub-
strates (12.5 WM each) by the sPLA2 from bovine pancreas. A:
Equimolar mixture of PAPC and PAPC-OOH. B: Equimolar mix-
ture of PAPC and PAPC-OH. The values for the liberation of AA
(8), 15-HpETE (E) and 15-HETE (O) are expressed as molar per-
centages of the initial total amount of phospholipids in the sample.
AA values represent the mean þ S.D. of four separate experiments.
The values of 15-HpETE and 15-HETE represent the mean of two
experiments. Other conditions as in Fig. 1.
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approximately three and eight times higher than that of 15-
HpETE and 15-HETE, respectively (Fig. 2). Moreover, the
initial rates of the liberation of AA with the equimolar mix-
tures of PAPC and PAPC-OOH or PAPC-OH were about
two to three times higher than with pure PAPC (cf. Figs. 1
and 2). Similar, albeit less pronounced e¡ects were obtained
with 1:10 mixtures of lipoxygenated and parent phospholipids
(not shown). These observations are in sharp contrast to the
work of Jung et al. who interpreted their results with porcine
pancreas sPLA2 as a preferred action on the lipoxygenated
phospholipid on an analogous equimolar mixture within the
¢rst 30 s [8]. However, these authors measured the activity at
10‡C at which the physicochemical structure of the phospho-
lipids is di¡erent from that under physiological conditions in
mammalian cells. Our data suggest a triggering by 15-lipoxy-
genation of the PLA2-mediated liberation of AA from phos-
pholipids.
Similar results were also obtained with snake venom sPLA2
(Table 1). Again, higher enzymatic rates were observed with
the pure 15-lipoxygenated phospholipids than with non-lip-
oxygenated PAPC, but in equimolar mixtures of PAPC and
PAPC-OOH or PAPC-OH the PAPC proved to be the pre-
ferred substrate. Unlike the sPLA2 from bovine pancreas,
however, in our hands the snake venom enzyme did not reveal
a facilitated liberation of AA from PAPC in the presence of
equimolar amounts of 15-lipoxygenated phospholipids. This
di¡erence may be due to di¡erent experimental conditions
when having measured this enzyme (higher pH, lower temper-
ature, see Section 2). An enhancement of the AA liberation by
C. adamanteus PLA2, however, has been reported by other
authors in the presence of 8% 1-palmitoyl-2-hydroperoxylino-
leyl phosphatidylcholine at pH 7.8 and 37‡C [23]. Therefore it
is reasonable to assume that triggering of the liberation of AA
by the presence of lipoxygenated phospholipids is a general
property of sPLA2s.
3.2. Experiments with the 85 kDa cytosolic phospholipase A2
Upon reaction of cPLA2 with lipoxygenated and non-lip-
oxygenated phospholipids, comparable initial rates of fatty
acid liberation were obtained from pure non-lipoxygenated
and parent phospholipids (Fig. 3). The time courses of these
reactions were principally similar to those obtained with pan-
creatic sPLA2 (Fig. 1) and may re£ect progressive inhibition
of cPLA2 by accumulating 15-H(p)ETE. To our knowledge,
this is the ¢rst direct evidence that cPLA2 is capable of lib-
erating 15-H(p)ETE from the corresponding phospholipids.
This property is not in line with the general assumption in
the literature that the action of cPLA2 would be speci¢c for
AA release, which was solely deduced from the fact that
cPLA2 liberated selectively AA from a mixture of cellular
phospholipids [26].
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Fig. 3. sn-2 cleavage of pure non-lipoxygenated (PAPC) and 15-lip-
oxygenated (PAPC-OOH or PAPC-OH) substrates by the 85 kDa
cPLA2. Conditions and symbols as in Fig. 1. The values for the lib-
eration of AA represent the mean þ S.D. of four separate experi-
ments, for that of 15-HpETE and 15-HETE the mean of two ex-
periments.
Fig. 4. sn-2 cleavage of equimolar mixtures of non-lipoxygenated
(PAPC) and 15-lipoxygenated (PAPC-OOH or PAPC-OH) sub-
strates by the 85 kDa cPLA2. A: Equimolar mixture of PAPC and
PAPC-OOH. B: Equimolar mixture of PAPC and PAPC-OH. Con-
ditions and symbols as in Fig. 2. The values for the liberation of
AA represent the mean þ S.D. of three separate experiments, for
that of 15-HpETE and 15-HETE sets of single experiments.
Table 1
Action of sPLA2 from C. adamanteus venom on non-lipoxygenated and 15-lipoxygenated sn-2-arachidonoyl phosphatidylcholines in pure state
and in equimolar mixtures
Substrate(s) AA liberation (WM/min) 15-H(p)ETE liberation (WM/min)
25 WM PAPC 2.82 (2) ^
25 WM PAPC-OOH ^ 4.08 (2)
25 WM PAPC-OH ^ 5.20 (2)
12.5 WM PAPC+12.5 WM PAPC-OOH 2.00 þ 0.41 (3) 0.55 þ 0.02 (3)
12.5 WM PAPC+12.5 WM PAPC-OH 2.01 þ 0.28 (3) 0.76 þ 0.02 (3)
The time courses of the liberation of AA and of 15-H(p)ETE were obtained in a similar manner as in the experiments in Figs. 1 and 2. The values
representing the linear parts of the kinetics after 1 min are given. Numbers of experiments are denoted in parentheses.
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In equimolar mixtures of lipoxygenated and non-lipoxygen-
ated substrates, however, again PAPC turned out to be the
preferential substrate, but a small, but signi¢cant liberation of
15-H(p)ETE was found under these conditions as well (Fig.
4). Therefore, in cells cPLA2 may be involved not only in the
liberation of AA but also in that of 15-HETE under condi-
tions at which its action is preceded by that of 15-lipoxyge-
nase. Unlike other authors who used complex mixtures of
phospholipids supplemented with 10% 1-palmitoyl-2-hydro-
peroxylinoleyl phosphatidylcholine as substrate for the cPLA2
[23], we failed to observe a triggering of AA liberation from
PAPC by the presence of PAPC-(O)OH.
4. Discussion
Using three di¡erent PLA2s we clearly demonstrated that
pure de¢ned 15-lipoxygenated phospholipids are better sub-
strates than the corresponding parent phospholipid which is in
line with other reports using other enzymes and methods [22].
The progressive inhibition by liberated 15-H(p)ETE during
prolonged reaction periods in the closed system observed by
us should not occur in vivo since they are either bound to
serum albumin or metabolised. In mixtures of lipoxygenated
and non-lipoxygenated phospholipids, however, this prefer-
ence was reversed with all three enzymes. This observation
is not compatible with the putative function of repair enzymes
toward peroxidative damage to membrane phospholipids as
often proposed, inasmuch as a preferential liberation of AA
would give rise to accumulation of esteri¢ed oxygenated fatty
acids in the phospholipid mixture. It is conceivable that other
PLA2s not studied hitherto are responsible for the removal of
oxygenated polyenoic fatty acids from oxidatively damaged
membrane phospholipids in the cell. Another explanation
could be a modi¢cation of the reaction speci¢city of PLA2s
by other membrane constituents. In this connection we refer
to a recent work by Kampayashi et al. who observed a pref-
erential action of Crotalus adamanteus venom PLA2 on hydro-
peroxylinoleyl phosphatidylcholine if its concentration in the
phospholipid mixture was below 10 mol% with concomitant
presence of 25 mol% of cholesterol [24]. In the light of this
discrepancy our results with de¢ned model substrates con-
struct a fundamental basis for the future work under condi-
tions which correspond to the cellular environment.
Another important observation in our study is that 15-lip-
oxygenation of phospholipids appears to trigger the liberation
of AA rather than that of 15-HETE. This triggering of the
liberation of AA by concomitantly present PAPC-O(O)H can-
not be accounted for by a detergent-like action of the latter,
inasmuch as under our experimental conditions such an e¡ect
did not occur in the presence of the corresponding lysophos-
pholipid (data not shown) which is more amphipathic than
PAPC-O(O)H. Moreover, with red blood cells we failed to
detect any cell-lytic action of PAPC-O(O)H at the concentra-
tions used. It is generally accepted that the di¡erent reactions
with lipoxygenated and non-lipoxygenated substrates or their
mixtures may re£ect di¡erent structures of the phospholipid
liposomes or micelles rather than genuine di¡erences in sub-
strate speci¢city.
Assuming that this e¡ect of 15-lipoxygenated phospholipids
also occurs with the physiologically relevant sPLA2 types in
in£ammatory cells, which is currently under investigation in
our laboratory, it would reveal a novel possible biological
function of 15-lipoxygenases in the AA metabolic cascade
wherein the action of 15-lipoxygenase precedes that of sPLA2
and stimulates by this way the release of AA via the classical
reaction cascade. Besides direct lipoxygenation of phospholi-
pids, 15-lipoxygenated phospholipids can also be formed by
esteri¢cation of lysophospholipids with the corresponding free
hydroxy-polyenoic fatty acid, e.g. 15-HETE. The latter reac-
tion has been reported to in£uence signal transduction proc-
esses [27^32]. In conclusion, 15-lipoxygenase processing of
arachidonoyl phospholipids as well as incorporation of 15-
HETE into phospholipids may modify the sn-2 cleavage by
PLA2s, and thus, signal transduction processes in a complex
manner.
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